1.Research Progress on Pathogenesis and Targeted Intervention Strategies of Chinese Herbal Active Components in Autism Spectrum Disorder: A Review
Lyuyuan LIANG ; Jialei CAO ; Shengjia DING ; Qirong WANG ; Yiping WANG ; Fangyuan CHEN ; Fengzhen GUO ; Yunkai WANG ; Yuxin ZHANG ; Yuxin LI ; Bingqi WEI ; Bingxiang MA ; Weili DANG
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(19):303-314
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with rapidly increasing global prevalence, characterized by core symptoms of social communication deficits and stereotyped repetitive behaviors. Although genetic predisposition, abnormal epigenetic regulation, perinatal environmental exposure, and nutritional-metabolic imbalances are recognized as major risk factors, the precise etiological mechanisms remain incompletely understood. Current clinical management primarily relies on behavioral interventions, with limited pharmacological options accompanied by adverse effects. Recent studies have demonstrated the unique therapeutic value of active components from Chinese herbal medicine in ASD intervention. This article reviews the mechanisms underlying various Chinese herbal active components in ASD treatment, including improvements in synaptic dysfunction, blood-brain barrier impairment, neurotransmitter regulation, cerebellar dysfunction, immune dysregulation and neuroinflammation, oxidative stress, programmed neuronal cell death, and lipid metabolism. These bioactive components exhibit multi-target and multi-pathway regulatory effects, providing novel therapeutic strategies and directions for ASD.
2.Carthamus tinctorius L.-derived nanovesicles alleviate cardiomyocyte hypertrophy by inhibiting the NF-κB signaling pathway
Guojun ZHANG ; Zhongpeng DU ; Lu WANG ; Junyu CHEN ; Huanjun RUAN ; Ye LUO ; Weili DUAN ; Shiyu CHEN ; Teng LI ; Xiao KE
Acta Universitatis Medicinalis Anhui 2026;61(8):1416-1423
ObjectiveTo investigate whether Carthamus tinctorius L.-derived nanovesicles (CDNVs) can alleviate angiotensin Ⅱ (ANGⅡ)-induced cardiomyocyte (H9C2) hypertrophy by inhibiting the NF-κB signaling pathway and to elucidate the underlying molecular mechanisms. MethodsCDNVs were isolated and purified by ultracentrifugation combined with sucrose density gradient centrifugation, and their morphology and particle size distribution were identified by transmission electron microscopy and nanoparticle tracking analysis. Rat H9C2 cardiomyocytes were cultured in vitro and randomly divided into the normal control group (NC), ANGⅡ (1.0 μmol/L) group, ANGⅡ+CDNVs group, and ANGⅡ+CDNVs+NF-κB activator 1 group. After 24 h of intervention, cell viability was detected by the CCK-8 assay, the expression of myocardial hypertrophy-related genes (ANP, BNP) was determined by qPCR, the relative cell area was measured by phalloidin staining, the expression of hypertrophy marker proteins and NF-κB pathway proteins (P-p65/p65, P-IκBα/IκBα) was examined by Western blot, and nuclear translocation of p65 was observed by immunofluorescence. Subsequently, NF-κB signaling pathway agonist activator 1 was added, and the expression of myocardial hypertrophy marker proteins and NF-κB pathway proteins was detected. ResultsCDNVs exhibited a typical round-like vesicle structure with an average particle size of 140.4 nm, which was consistent with the morphological characteristics of exosomes. ANGⅡ at concentrations of 0.1-1.0 μmol/L had no significant effect on cardiomyocyte viability. Compared with the NC group, ANGⅡ significantly upregulated the gene expression of ANP and BNP, increased the relative surface area of cardiomyocytes, elevated the levels of myocardial hypertrophy marker proteins and NF‑κB pathway proteins, and promoted the nuclear translocation of p65 (P<0.05). Following treatment with CDNVs, all the above indicators were markedly reduced in comparison with the ANGⅡ group (all P<0.05). However, all these experimental results were reversed after the addition of an NF‑κB agonist. ConclusionCDNVs alleviate ANGⅡ-induced H9C2 cell hypertrophy by inhibiting the NF-κB signaling pathway.
3.Toxic Mechanism, Risk Evaluation, and Regulatory Policies of Pyrrolizidine Alkaloids from Senecionis Scandentis Herba: A Review
Weili CHEN ; Shengxuan LI ; Linying QIN ; Xiangle MENG ; Yu DONG ; Long CHENG
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(21):330-338
ObjectiveTo summarize the research results on the toxic mechanism and the relevant regulatory policies at home and abroad of pyrrolizidine alkaloids (PAs), the main toxic components, in Senecionis Scandentis Herba, thereby providing insights into the clinical use and scientific regulation of Senecionis Scandentis Herba. MethodsMultiple Chinese and English databases including PubMed, ScienceDirect, Elsevier, China national knowledge infrastructure (CNKI), Wanfang Data, and VIP were searched, with "Senecio," "PSenecio scandens," and "pyrrolizidine alkaloids" as search terms. The relevant articles published from 1959 to 2025 were retrieved and analyzed, and 79 articles were finally selected for review. ResultsThe chemical components of Senecionis Scandentis Herba include alkaloids, flavonoids, volatile oils, sesquiterpenes, jacaranone derivatives, and organic acids, among which alkaloids are the most toxic components, followed by jacaranone derivatives. PAs are metabolized into highly active pyrrole derivatives in the liver, which can cause serious adverse reactions such as sinusoidal obstruction syndrome and DNA damage. The content of PAs varies significantly due to the origin, harvest period, and medicinal parts. There have been reports of clinical liver injury caused by preparations containing Senecionis Scandentis Herba, and some preparations have a daily intake of PAs exceeding the international safety threshold. Currently, international organizations have set limited standards for PAs, while China only controls the content of adonifoline, and the supervision is not yet perfect. ConclusionAlthough Senecionis Scandentis Herba has medicinal value, its PAs have significant toxicological properties. This is a problem that cannot be ignored and needs to be overcome in the use of Senecionis Scandentis Herba. Therefore, it is necessary to strengthen the quality control of raw materials, establish a more comprehensive limited standard for PAs, and optimize the medication strategy in combination with traditional Chinese medicine theory to ensure the safety of clinical medication.
4.Toxic Mechanism, Risk Evaluation, and Regulatory Policies of Pyrrolizidine Alkaloids from Senecionis Scandentis Herba: A Review
Weili CHEN ; Shengxuan LI ; Linying QIN ; Xiangle MENG ; Yu DONG ; Long CHENG
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(21):330-338
ObjectiveTo summarize the research results on the toxic mechanism and the relevant regulatory policies at home and abroad of pyrrolizidine alkaloids (PAs), the main toxic components, in Senecionis Scandentis Herba, thereby providing insights into the clinical use and scientific regulation of Senecionis Scandentis Herba. MethodsMultiple Chinese and English databases including PubMed, ScienceDirect, Elsevier, China national knowledge infrastructure (CNKI), Wanfang Data, and VIP were searched, with "Senecio," "PSenecio scandens," and "pyrrolizidine alkaloids" as search terms. The relevant articles published from 1959 to 2025 were retrieved and analyzed, and 79 articles were finally selected for review. ResultsThe chemical components of Senecionis Scandentis Herba include alkaloids, flavonoids, volatile oils, sesquiterpenes, jacaranone derivatives, and organic acids, among which alkaloids are the most toxic components, followed by jacaranone derivatives. PAs are metabolized into highly active pyrrole derivatives in the liver, which can cause serious adverse reactions such as sinusoidal obstruction syndrome and DNA damage. The content of PAs varies significantly due to the origin, harvest period, and medicinal parts. There have been reports of clinical liver injury caused by preparations containing Senecionis Scandentis Herba, and some preparations have a daily intake of PAs exceeding the international safety threshold. Currently, international organizations have set limited standards for PAs, while China only controls the content of adonifoline, and the supervision is not yet perfect. ConclusionAlthough Senecionis Scandentis Herba has medicinal value, its PAs have significant toxicological properties. This is a problem that cannot be ignored and needs to be overcome in the use of Senecionis Scandentis Herba. Therefore, it is necessary to strengthen the quality control of raw materials, establish a more comprehensive limited standard for PAs, and optimize the medication strategy in combination with traditional Chinese medicine theory to ensure the safety of clinical medication.
5.Research progress of clock gene Period family in head and neck squamous cell carcinoma
Yongying YE ; Yan ZOU ; Tianming CHEN ; Weili WU
Journal of International Oncology 2025;52(2):113-118
Head and neck squamous cell carcinoma (HNSCC) is the most common type of heterogeneous malignant tumor. Over 60% of HNSCC patients are at locally advanced stage at the time of diagnosis. Despite the emergence of advanced diagnosis and treatment measures, the prognosis of patients with recurrent or metastatic HNSCC remains poor. The Period (PER) gene family is an important member of the circadian clock genes, with family members PER1, PER2, and PER3 showing differential expression in HNSCC, participating in biological processes such as proliferation, apoptosis, invasion, or metastasis of tumor cells. In most studies, they exhibit anti-cancer effects and are closely related to the tumor microenvironment, immunotherapy, chronotherapy, etc., making them potential biomarkers. A comprehensive analysis of the expression of PER gene family in HNSCC, its biological role in the occurrence and development of tumor and the corresponding molecular biological mechanism is helpful to explore its potential application value in the diagnosis and treatment of HNSCC.
6.Genetic re-analysis of a Chinese pedigree affected with Hypertrophic cardiomyopathy due to a heterozygous truncating variant of ALPK3 gene and literature review.
Chenliang HONG ; Xianhong DING ; Yang LU ; Jia ZHU ; Jinwei WANG ; Mengyi XU ; Shuaishuai CHEN ; Bo SHEN ; Weili GE
Chinese Journal of Medical Genetics 2025;42(11):1337-1346
OBJECTIVE:
To explore the clinical and genetic characteristics of a Chinese pedigree affected with Hypertrophic cardiomyopathy (HCM) due to a truncating variant of ALPK3 gene.
METHODS:
A 44-year-old male admitted to Taizhou Hospital of Zhejiang Province on December 29, 2018 was selected as the study subject. Whole-exome sequencing (WES) was carried out, and candidate variant was interpreted by following the guidelines from the American College of Medical Genetics and Genomics (ACMG). For ALPK3 was considered an autosomal recessive gene, the WES results was considered insufficient to explain his phenotype. In April 2023, the proband's WES data were re-analyzed using updated annotation pipelines, and peripheral blood samples were collected from his first-degree relatives (mother and brother) for Sanger sequencing validation. Conservation analysis and protein structural modeling were performed to assess the impact of the variant. Clinical evaluation and genetic counseling were provided to the proband's family members. Relevant literature on ALPK3tv-induced HCM patients were searched in Wanfang Data Knowledge Service Platform, CNKI, and PubMed database using "ALPK3" and "hypertrophic cardiomyopathy" as keywords. Clinical characteristics of HCM patients with heterozygous ALPK3tv variants were summarized and compared with the clinical characteristics of HCM patients with positive sarcomere-associated gene variants (SARC+). This study was approved by the Medical Ethics Committee of Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University (Ethics No.: K20230314).
RESULTS:
The proband was a 44-year-old male who was transferred to our institution on December 29, 2018 due to "chest tightness and pain for 6 months, exacerbated for 2 days". Emergency coronary angiography was performed, which led to a preliminary diagnosis of "acute coronary syndrome", and the patient was admitted to the Cardiology Department for treatment. Based on electrocardiogram and echocardiogram findings, the diagnosis was revised as HCM. The patient's condition has stabilized post-coronary angiography, and he was discharged with improved condition. On January 2019, WES was conducted to determine the etiology of the proband's HCM. WES results identified a novel heterozygous c.2156dupC (p.Pro720ThrfsTer53) truncating variant in the ALPK3 gene. At that time, the inheritance pattern could not explain the phenotype. In 2022, a literature indicated that heterozygous ALPK3tv could lead to autosomal dominant HCM. Consequently, in April 2023, the proband's whole-exome data were re-annotated, revealing changes in the transcript and protein versions, with the updated site annotated as ALPK3 (NM_020778.5): c.1550dupC (p.Pro518ThrfsTer53). Sanger sequencing confirmed that the proband's mother and brother also carried this variant. The mother exhibited obstructive HCM, while the brother showed no related phenotype. Bioinformatics analysis demonstrated conservation of this site across multiple species, and the variant has resulted in the loss of a protein domain. Based on ACMG guidelines, the variant was classified as likely pathogenic. Literature review and Bayesian calculation further elevated the pathogenicity rating, indicating that this variant was the cause of HCM in the patient. Literature study revealed distinctions between HCM caused by this variant type and SARC+ HCM. The age of onset among heterozygous ALPK3tv patients was delayed by approximately 10 years compared to SARC+ patients. Both forms of HCM exhibited a male predominance, which was particularly marked in individuals with ALPK3tv. Electrocardiographic left ventricular hypertrophy was more prevalent in heterozygous ALPK3tv patients than in SARC+ patients. The incidence of apical or concentric hypertrophy patterns was higher in heterozygous ALPK3tv patients compared to asymmetric septal hypertrophy, which predominated in SARC+ patients. ALPK3tv patients exhibited lower penetrance and later onset compared to SARC+ patients. A positive correlation between left ventricular wall thickness and age was noted in female patients only.
CONCLUSION
In this pedigree, the proband has presented with HCM, characterized by echocardiographic evidence of apical left ventricular hypertrophy without significant outflow tract obstruction or extracardiac phenotypes. Although his mother and brother had carried the same heterozygous ALPK3 (NM_020778.5) c.1550dupC (p.Pro518ThrfsTer53), the mother exhibited severe obstructive HCM, while the brother was asymptomatic, suggesting incomplete or age-dependent penetrance within the family. This study has enriched the evidence for the pathogenicity of ALPK3tv among Chinese HCM pedigrees and underscored the importance of periodic literature reviews and genetic re-analysis for unresolved genetic testing results.
Humans
;
Male
;
Pedigree
;
Adult
;
Cardiomyopathy, Hypertrophic/genetics*
;
Heterozygote
;
Asian People/genetics*
;
Exome Sequencing
;
Mutation
;
China
;
Female
;
East Asian People
7.Risk management of catheterization room in interventional therapy of congenital heart disease in children
Lijun DAI ; Weili YANG ; Yanru CHEN
China Modern Doctor 2025;63(18):5-8
Objective To investigate the application of catheterization laboratory risk management in the interventional treatment of children with congenital heart disease(CHD),aiming to construct a comprehensive and practical risk management intervention plan to enhance treatment safety and child patient experience.Methods A total of 120 pediatric patients who underwent interventional treatment in the Pediatric Cardiovascular Department of the Interventional Center of Imaging and Nuclear Medicine,the Second Affiliated Hospital of Wenzhou Medical University from January 2021 to December 2022 were randomly divided into two groups(60 cases in each group).Child patients in control group received routine care,while child patients in observation group were subjected to a risk management strategy of the catheterization laboratory on the basis of control group,which included preoperative assessment,psychological intervention,intraoperative monitoring and prevention,stress management and postoperative care.Mental health status of the children,incidence of risk events and nursing disputes,as well as satisfaction of two groups were compared.Results Under the risk management strategy,the levels of anxiety and depression in observation group significantly decreased,with anxiety score dropping from(56.8±4.6)before treatment to(30.8±2.6)after treatment,and depression score falling from(55.8±2.5)to(31.4±1.6),demonstrating a significant improvement(P<0.01).After implementing the risk management strategy,the incidence of risk events in observation group was notably lower than that in control group(5.0%vs.15.0%),and medical disputes were also significantly reduced(3.3%vs.11.7%).The overall satisfaction rate in observation group was 95.0%,significantly higher than 78.3%in control group(P=0.0012).Conclusion A comprehensive risk management plan can effectively reduce the incidence of risk events and medical disputes in the interventional treatment of pediatric CHD,significantly improving child patient satisfaction and mental health status.This confirms the vital role of risk management strategies in optimizing the treatment process,reducing adverse events,and enhancing doctor-patient harmony,providing clinical reference of safer interventional treatment services for children with CHD.
8.Assessment of efficacy and safety of first-line EGFR-TKI combined with radiotherapy in EGFR-mutant lung cancer with brain metastases
Xin YIN ; Yanhua ZHOU ; Weili YI ; Jian HUANG ; Mengting LAI ; Zhili CHEN ; Dongning HUANG ; Li QIN
Chinese Journal of Radiation Oncology 2025;34(11):1102-1110
Objective:To evaluate the efficacy and safety of combining third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) with brain radiotherapy in patients with newly diagnosed EGFR mutation-positive non-small cell lung cancer (NSCLC) with brain metastases. Methods:A retrospective analysis was performed on the clinical data of patients with newly diagnosed EGFR-mutant NSCLC with brain metastases who received first-line treatment with third-generation EGFR-TKI with or without brain radiotherapy at the Fourth Affiliated Hospital of Guangxi Medical University between January 2018 and December 2022. Patients treated with EGFR-TKI plus brain radiotherapy were assigned to the combination group, while those treated with EGFR-TKI alone were assigned to the monotherapy group. Intracranial progression-free survival (iPFS), progression-free survival (PFS), overall survival (OS), intracranial disease control rate (iDCR), intracranial objective response rate (iORR), and adverse events were compared between groups. Subgroup analyses were performed according to EGFR exon 19 deletion (19del) and exon 21L858R mutation status. Survival was estimated using the Kaplan-Meier method, with the log-rank test applied for group comparisons and univariate analysis, while multivariate analysis was conducted using Cox proportional hazards regression model. Results:A total of 107 patients were included: 57 (53%) in the monotherapy group and 50 (47%) in the combination group. The combination therapy significantly improved iORR (80% vs. 60%, P=0.023), prolonged median OS (37.7 vs. 31.6 months, P=0.004), and extended median iPFS (21.8 vs. 16.7 months, P=0.018). The iDCR was 100% in both groups, and the difference in median PFS was not statistically significant (18.6 vs. 15.2 months, P=0.086). In the 19del subgroup ( n=53), patients in the combination group had longer OS ( P=0.028) and iPFS ( P=0.028). In the 21L858R subgroup ( n=54), the median OS was also longer in the combination group ( P=0.050). Multivariate analysis identified TKI monotherapy and an Eastern Cooperative Oncology Group (ECOG) performance status score=2 as independent adverse prognostic factors for iPFS, while TKI monotherapy, age ≥65 years, ECOG score=2, and >3 brain metastases were the independent adverse prognostic factors for OS. The incidence of adverse events did not differ significantly between groups (all P>0.05). Conclusions:First-line combination therapy with third-generation EGFR-TKI and cranial radiotherapy provides superior efficacy and acceptable safety compared with EGFR-TKI monotherapy in patients with EGFR-mutant lung adenocarcinoma and brain metastases. Both EGFR 19del and 21L858R mutation subgroups benefit from the combined treatment approach.
9.Expert consensus on surgical treatment and rehabilitation for competitive sports athletes returning to sports after anterior cruciate ligament injury (version 2025)
Kai HUANG ; Lunhao BAI ; Qing BI ; Hong CHEN ; Jiwu CHEN ; Xuesong DAI ; Wenyong FEI ; Weili FU ; Zhizeng GAO ; Lin GUO ; Yinghui HUA ; Jingmin HUANG ; Suizhu HUANG ; Xuan HUANG ; Jian LI ; Qiang LI ; Shuzhen LI ; Yanlin LI ; Yunxia LI ; Zhong LI ; Ning LIU ; Yuqiang LIU ; Wei LU ; Hongbin LYU ; Haile PAN ; Xiaoyun PAN ; Chao QI ; Weiliang SHEN ; Luning SUN ; Jin TANG ; Zimin WANG ; Bide WANG ; Ru WANG ; Shaobai WANG ; Licheng WEI ; Weidong XU ; Yongsheng XU ; Jizhou YANG ; Liang YANG ; Rui YANG ; Hongbo YOU ; Tengbo YU ; Jiakuo YU ; Bing YUE ; Hua ZHANG ; Hui ZHANG ; Qingsong ZHANG ; Xintao ZHANG ; Jiajun ZHAO ; Lilian ZHAO ; Qichun ZHAO ; Song ZHAO ; Jiapeng ZHENG ; Jiang ZHENG ; Zhi ZHENG ; Jingbin ZHOU ; Jinzhong ZHAO
Chinese Journal of Trauma 2025;41(4):325-338
With the rapid development of competitive sports, the incidence of anterior cruciate ligament (ACL) injury is on the rise. Such injuries may shorten athletes′ career and lead to other long-term adverse consequences. Although athletes generally recover well after ACL reconstruction, many still struggle to return to their pre-injury performance levels. Advances in the understanding of ACL anatomy and injury mechanisms, along with the evolution of surgical techniques and rehabilitation methods, have provided more individualized and tailored options for athletes following ACL injuries. However, there is currently no consensus in China regarding surgical and rehabilitation strategies for competitive athletes aiming to return to sports after ACL injuries. To this end, the Sports Medicine Committee of the Chinese Research Hospital Association and the Editorial Board of the Chinese Journal of Trauma jointly formulated the Expert consensus on surgical treatment and rehabilitation for competitive sports athletes returning to sports after anterior cruciate ligament injury ( version 2025), and presented 14 recommendations covering surgical indications, preoperative rehabilitation, surgical timing, surgical strategies and postoperative rehabilitation strategies, aiming to improve the surgical treatment and rehabilitation system for ACL injuries in competitive athletes and facilitate their return to high-level sports performance after injury.
10.Analysis of the association between moderate-to-vigorous-physical activity and obesity, poor sleep quality and multimorbidity in 7- to 8-year-old children in Shanghai City
Qiong YAN ; Weili CHEN ; Liting CHU ; Lijing SUN ; Xinyao LIAN ; Jianhui GUO ; Chunyan LUO ; Jing LI
Chinese Journal of Preventive Medicine 2025;59(11):1924-1931
Objective:To analyze the association between moderate-to-vigorous-physical activity (MVPA) and obesity, poor sleep quality, as well as multimorbidity in 7- to 8-year-old children in Shanghai City.Methods:From September to November 2023, a cluster sampling method was used to select second-grade students from four primary schools in Jinshan District, Shanghai. Three-axis acceleration motion sensors (GT3X+, Acti-graph) were used to monitor daily physical activity for seven consecutive days. A multivariate logistic regression model was used to analyze the association between MVPA duration characteristics and obesity, poor sleep quality and multimorbidity in school-age children.Results:Of the 937 study participants, 512 (54.64%) were boys and 425 (45.36%) were girls. Among them, 89 (9.50%) were obese and 782 (83.46%) had poor sleep quality. A total of 77 cases (8.22%) were affected by obesity and poor sleep quality. The average daily MVPA time was (45.97±15.87) minutes, and the MVPA attainment rate was 17.18%. The multivariate logistic regression model analysis showed that, after adjusting for covariates, the daily average MVPA time was negatively associated with the risk of obesity ( OR=0.982, 95% CI: 0.968-0.997), as well as multimorbidity ( OR=0.981, 95% CI: 0.965-0.997). The risk of obesity, poor sleep quality and multimorbidity in <1 d was 2.228 ( OR=2.228, 95% CI: 1.398-3.549), 1.702 ( OR=1.702, 95% CI: 1.141-2.540) and 2.150 ( OR=2.150, 95% CI: 1.310-3.528) times higher than that in ≥1 d. Conclusion:Obesity, poor sleep quality and multimorbidity of school-age children are closely related to the level of moderate-to-vigorous physical activity.

Result Analysis
Print
Save
E-mail